disease

ACN Newswire

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

indie 11 1 月

3 minutes

ROCKVILLE, MD and SHENZHEN, CH […]

JCN Newswire

Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

ruth 10 1 月

3 minutes

TOKYO, Jan 9, 2023 – (JC […]

JCN Newswire

Eisai’s Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer’s Disease, in Thailand

ruth 4 11 月

2 minutes

TOKYO, Nov 4, 2022 – (JC […]

JCN Newswire

U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab

ruth 6 7 月

3 minutes

TOKYO, Jul 6, 2022 – (JC […]

JCN Newswire

Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS

ruth 27 5 月

2 minutes

TOKYO, May 27, 2022 – (J […]

SeaPRwire

Supporting caregivers of diabetic patients paramount in war against the disease: Chan Chun Sing

aseanpr 14 5 月

0 min

JCN Newswire

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

ruth 10 5 月

9 minutes

TOKYO and CAMBRIDGE, Mass., Ma […]

JCN Newswire

Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine

ruth 18 4 月

4 minutes

OSAKA, Japan and TOKYO, Japan, […]

JCN Newswire

Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting

ruth 11 3 月

3 minutes

TOKYO, Mar 11, 2022 – (J […]

JCN Newswire

Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM

ruth 28 1 月

9 minutes

Cambridge, MA, Jan 28, 2022 &# […]

SeaPRwire

Death of woman, 39, due to heart disease, not Covid-19 jab: S’pore heart centres

aseanpr 27 1 月

0 min

JCN Newswire

Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

ruth 19 1 月

6 minutes

TOKYO, Jan 19, 2022 – (J […]

JCN Newswire

Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

ruth 12 11 月

4 minutes

TOKYO, Nov 12, 2021 – (J […]

JCN Newswire

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease

ruth 9 11 月

7 minutes

TOKYO, Nov 9, 2021 – (JC […]

JCN Newswire

Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study

ruth 4 11 月

2 minutes

TOKYO, Nov 4, 2021 – (JC […]

SeaPRwire

Researchers identify possible predictor of early heart disease in the elderly: NHCS

aseanpr 1 9 月

3 minutes

SINGAPORE – Researchers […]

JCN Newswire

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

ruth 30 7 月

4 minutes

TOKYO, Jul 30, 2021 – (J […]

JCN Newswire

Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

ruth 27 7 月

5 minutes

TOKYO, Jul 27, 2021 – (J […]

JCN Newswire

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer’s Disease and Dementia at AAIC 2021

ruth 21 7 月

3 minutes

TOKYO, Jul 21, 2021 – (J […]

JCN Newswire

Biogen and Eisai launch initiatives to help patients with Alzheimer’s disease access ADUHELM

ruth 8 6 月

7 minutes

Cambridge, MA, Jun 8, 2021 […]

2026 年 4 月
一	二	三	四	五	六	日
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30